NasdaqGS - Delayed Quote USD

ALX Oncology Holdings Inc. (ALXO)

0.5587

+0.0732

+(15.08%)

At close: June 2 at 4:00:02 PM EDT

0.5700

+0.01

+(2.02%)

After hours: June 2 at 7:58:12 PM EDT

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that management will participate in the Jefferies 2025 Global Healthcare Conference. Details are as follows: Format: Fireside Chat Date: Thursday, June 5, 2025Time: 1:25 PM ETLocation: New York, NYWebcast link: A

GlobeNewswire 3 days ago

ALXO
+15.08%
ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window by reducing toxicity - Following recent IND clearance from U.S. FDA, ALX2004 will enter clinical studies mid-year 2025 with initial safety data anticipated in 1H 2026 - Trials evaluating the Company’s lead investigational therapy, CD47-blocker evorpacept, in breast and colorectal canc

GlobeNewswire 13 days ago

ALXO
+15.08%
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that it will host a webcast event on May 20, 2025, to provide an update on ALX2004, the Company’s potentially best- and first-in-class investigational antibody-drug conjugate (ADC). The webcast will highlight the

GlobeNewswire 20 days ago

ALXO
+15.08%
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies in mid-2025 IND clearance received from U.S. FDA for novel EGFR-targeted antibody-drug conjugate (ADC), ALX2004, paving way for mid-year clinical program initiation; Company to host webcast focused on ALX2004 research program on May 20Company will not pursue U.S. registrational

GlobeNewswire 25 days ago

ALXO
+15.08%
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced plans to report its first quarter 2025 financial results on Thursday, May 8th, 2025, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. A

GlobeNewswire last month

ALXO
+15.08%
ALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trials

Despite the failures, ALX Oncology remains hopeful about evorpacept and is focusing on combination trials with other anti-cancer antibodies.

Clinical Trials Arena last month

ALXO
+15.08%

ABBV
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R2) was well-tolerated and demonstrated promising anti-tumor activity - Combination generated complete responses (CR) in 83% of patients with indolent relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) comparing favorably to 34% historical CR rate with R2 alone - Phase 2 portion of trial in patients with previously untreat

GlobeNewswire last month

ALXO
+15.08%
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

In ASPEN-03 and ASPEN-04 trials, efficacy data do not support advancing evorpacept in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), into a registrational studyCompany remains confident in continuing to pursue evorpacept in multiple clinical trials, based on the different mechanism of evorpacept in combination with anti-cancer antibodies, as evidenced by durable clinical response and consistent safety data in prior clinical trials SOUTH SAN FRANCISCO, April 25, 2025 (GLOB

GlobeNewswire last month

ALXO
+15.08%
ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate

ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology’s proprietary linker-payload platformALX2004, the company’s first ADC, was fully designed and developed in-house by ALX Oncology scientistsCompany expects to initiate Phase 1 clinical trials of ALX2004 in mid-2025, with initial safety data available in 1H 2026 SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- ALX Oncology

GlobeNewswire last month

ALXO
+15.08%
ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

ALX Oncology Holdings (ALXO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks 2 months ago

ALXO
+15.08%
Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday

We recently published an article titled Micro-, Small-Cap Firms Dominate Market Rally. In this article, we are going to take a look at where ALX Oncology Holdings Inc. (NASDAQ:ALXO) stands against the other stocks. The stock market pulled back to the red territory on Thursday, with all major indices posting significant losses as tariff threats continued […]

Insider Monkey 2 months ago

ALXO
+15.08%

^GSPC
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

– Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in patients with HER2-positive gastric cancer in an oral presentation at 2025 ASCO GI – Presented Phase 1b/2 data demonstrating evorpacept in combination with zanidatamab generates promising anti-tumor activity in advanced breast cancer at SABCS 2024 – Announced focused development plan during R&D Day, including introduction of clinical trials evaluating e

GlobeNewswire 2 months ago

ALXO
+15.08%
ALX Oncology to Cut Workforce by 30% to Support New Clinical Initiatives

ALX Oncology (ALXO) said Wednesday that it has made certain strategic changes, including reducing it

PREMIUM
MT Newswires 2 months ago

ALXO
+15.08%
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

Event to include updates on ongoing evorpacept clinical development program and introduction of clinical trials in breast and colorectal cancersAdvancing novel EGFR-targeted antibody-drug conjugate (ADC) candidate, ALX2004, into clinical-stage development with IND submission planned for Q1 2025Company implements strategic prioritization, resource optimizations and reductions to extend cash runway into Q4 2026 Webcast featuring company leadership and external key opinion leaders to take place tod

GlobeNewswire 2 months ago

ALXO
+15.08%
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced plans to report its fourth quarter and full year 2024 financial results on Thursday, March 6th, 2025, before market open. The company will not be hosting a teleconference in conjunction with its financial result

GlobeNewswire 3 months ago

ALXO
+15.08%
February 2025 US Penny Stocks With Promising Prospects

The U.S. stock market has been showing resilience, with the S&P 500 recently reaching an all-time high and major indices nearing record levels. In this climate, penny stocks—though often overlooked—can still offer intriguing opportunities for investors interested in smaller or newer companies. When backed by strong financials, these stocks may present a compelling mix of value and growth potential, making them worthy of consideration for those seeking promising prospects in the market.

Simply Wall St. 3 months ago

ALEC

BLND

ALXO
+15.08%
ALX Oncology to Host Virtual R&D Day on March 5, 2025

Company leadership and external key opinion leaders to highlight clinical program progress and provide business and financial updatesSOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced that it will host a virtual Research and Development (R&D) Day webcast on Wedn

GlobeNewswire 3 months ago

ALXO
+15.08%
ALX Oncology Shares Drop 15% Following Positive Phase 2

ALX Oncology reported positive updated data from its ASPEN-06 Phase 2 clinical trial.

GuruFocus.com 4 months ago

ALXO
+15.08%
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

Oral presentation at 2025 ASCO Gastrointestinal Cancers Symposium today highlights evorpacept as the first CD47 blocker to show substantial tumor response and a well-tolerated safety profile in a prospective randomized trialGreatest benefit observed among patients with confirmed HER2-positive cancer, as demonstrated by either fresh biopsy or ctDNA HER2-expression, with confirmed ORR of 48.9% and mDOR of 15.7 months vs. 24.5% ORR and mDOR of 9.1 months in the control group, and a PFS Hazard Ratio

GlobeNewswire 4 months ago

ALXO
+15.08%
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings, Inc. (“ALX Oncology” or the “Company”), (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced that effective January 21, 2025, the Compensation Committee of the Board of Directors of ALX Oncology granted an inducement stock option to purchase a total of 600,000 shares of ALX Oncology’s common stock to H

GlobeNewswire 4 months ago

ALXO
+15.08%

Performance Overview

Return	ALXO	S&P 500 (^GSPC)
YTD	-66.54%	+0.92%
1-Year	-94.74%	+12.48%
3-Year	-92.53%	+42.12%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ALX Oncology Holdings Inc. (ALXO)

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

ALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trials

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate

ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

ALX Oncology to Cut Workforce by 30% to Support New Clinical Initiatives

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

February 2025 US Penny Stocks With Promising Prospects

ALX Oncology to Host Virtual R&D Day on March 5, 2025

ALX Oncology Shares Drop 15% Following Positive Phase 2

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

Performance Overview